Anti-tumor Specific Immune Response in Head and Neck Cancers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

154 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-03-14

Study Completion Date

2021-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose is the description of anti-tumor immune responses in general and according to clinical stage and disease free survival (DFS: survival without recurrence (local or distant)) in patients with Head \& Neck Squamous Cell Carcinoma

Secondary purposes are:

* Study of relationship between anti-tumor immune response and qualitative (yes/no) and quantitative (number) presence of circulating tumor cells (CTCs);
* Study of relationship between qualitative (yes/no) and quantitative (number) presence of CTCs and clinical stage as well as DFS
* Study of relationship between anti-tumor immune response and clinical stage as well as DFS.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Role of Immune Activation in Response of Head and Neck Squamous Cell Carcinoma to Therapy

NCT01358097

Head and Neck Cancer Oropharyngeal Cancer Human Papillomavirus +1 more

COMPLETED

Predicting Immunotherapy Efficacy in Head and Neck Squamous Cell Cancer

NCT05296135

Head and Neck Squamous Cell Carcinoma

WITHDRAWN

Identification of Predictive Factors for the Response to Anti-Programmed Cell Death Protein 1 (PD1) Immunotherapy in Head and Neck Squamous Cell Carcinoma

NCT05328024

Head and Neck Cancer

RECRUITING

Study of Chemo-Immunotherapy in Head and Neck Cancer Patients

NCT01149902

Head and Neck Cancer

UNKNOWN PHASE1

Efficacy and Safety of Immunotherapy Combined With Neoadjuvant Chemotherapy in Patients With Locally Advanced HPV (-) Head and Neck Squamous Cell Carcinoma: a Phase II Clinical Trial

NCT04929067

Efficacy and Safety of Immunotherapy Combined With Neoadjuvant Chemotherapy in Patients With Locally Advanced HPV (-) HNSCC

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Head and Neck Squamous Cell Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

squamous cell carcinoma

Patients affected by Head \& Neck Squamous Cell Carcinoma. Blood sample at diagnosis, before any antitumor treatment

Blood sample

Intervention Type OTHER

Blood sample with 6 tube of blood (40 mL), after diagnosis and before any specific anticancer treatment

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood sample

Blood sample with 6 tube of blood (40 mL), after diagnosis and before any specific anticancer treatment

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient with Head \& Neck Squamous Cell Carcinoma after extension assessment, regardless of clinical stage (TNM UICC stage I-IV), before any medical or surgical treatment specifically directed against cancer (radiotherapy, surgery, chemotherapy or targeted therapy)
* Consent to participate to the study, non-opposition
* Affiliation to social security

Exclusion Criteria

* History of neoplasia, synchronous cancer, auto-immune disease, organ transplantation, chemotherapy
* HIV infection
* Corticotherapy during 15 days before blood sampling

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No